Outcome
| Type |
Measure |
Description |
Time frame |
Safety issue |
| Primary |
IAPT Definition of "Recovery" (Change between Baseline and Post-treatment) |
The IAPT criteria for 'Recovery' are met when patients move from 'caseness' at the beginning of the intervention (e.g., scoring >9 on the PHQ-9 or >7 on the GAD-7) to 'non-caseness' at the end of treatment (thus scoring below the cut-off) |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT Definition of "Recovery" (Change between baseline and 3 month follow-up) |
The IAPT criteria for 'Recovery' are met when patients move from 'caseness' at the beginning of the intervention (e.g., scoring >9 on the PHQ-9 or >7 on the GAD-7) to 'non-caseness' at the end of treatment (thus scoring below the cut-off) |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT Definition of "Recovery" (Change between baseline and 12 month follow-up) |
The IAPT criteria for 'Recovery' are met when patients move from 'caseness' at the beginning of the intervention (e.g., scoring >9 on the PHQ-9 or >7 on the GAD-7) to 'non-caseness' at the end of treatment (thus scoring below the cut-off) |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT Definition of "Reliable improvement" (Change between Baseline and Post-treatment) |
Reliable improvement is defined as when the patient has a 'reliable' decrease in their PHQ-9 / GAD-7 (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) score upon completion of their course of treatment |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT Definition of "Reliable improvement" (Change between baseline, and 3 month follow-up) |
Reliable improvement is defined as when the patient has a 'reliable' decrease in their PHQ-9 / GAD-7 (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) score upon completion of their course of treatment |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT Definition of "Reliable improvement" (Change between baseline and 12 month follow-up) |
Reliable improvement is defined as when the patient has a 'reliable' decrease in their PHQ-9 / GAD-7 (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) score upon completion of their course of treatment |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT definition of "Reliable recovery" (Change between Baseline and Post-treatment) |
Reliable recovery is defined as when the patient meets the criteria for both recovery and reliable improvement as defined above. Thus, a patient who moves from caseness to non-caseness, and also shows a 'reliable' (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) decrease in their symptom scores, is said to have a reliable recovery |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and post-treatment (week 12 of treatment) |
|
| Primary |
IAPT definition of "Reliable recovery" (Change between baseline and 3 month follow-up) |
Reliable recovery is defined as when the patient meets the criteria for both recovery and reliable improvement as defined above. Thus, a patient who moves from caseness to non-caseness, and also shows a 'reliable' (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) decrease in their symptom scores, is said to have a reliable recovery |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Primary |
IAPT definition of "Reliable recovery" (Change between baseline and 12 month follow-up) |
Reliable recovery is defined as when the patient meets the criteria for both recovery and reliable improvement as defined above. Thus, a patient who moves from caseness to non-caseness, and also shows a 'reliable' (reduction in PHQ-9 score of 6 or more, and reduction in GAD-7 score of 4 or more) decrease in their symptom scores, is said to have a reliable recovery |
GAD-7 and PHQ-9 which are used to compute this outcome measure are administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Work and Social Adjustment Scale (WSAS) - (Change between Baseline and Post-treatment) |
This is a simple, reliable and valid measure of impaired functioning. It is a 5-item self-report measure that provides an experiential impact of a disorder from the patient's point of view. It looks at how the disorder impairs the patient's ability to function day to day on five dimensions: work, social life, home life, private life and close relationships. This scale ranges from 0-40 with 40 indicating a severe level of functional impairment. |
Administered at baseline (initial screening) and post-treatment (week 12 of treatment) |
|
| Secondary |
Work and Social Adjustment Scale (WSAS) - (Change between baseline and 3 month follow-up) |
This is a simple, reliable and valid measure of impaired functioning. It is a 5-item self-report measure that provides an experiential impact of a disorder from the patient's point of view. It looks at how the disorder impairs the patient's ability to function day to day on five dimensions: work, social life, home life, private life and close relationships. This scale ranges from 0-40 with 40 indicating a severe level of functional impairment. |
Administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Work and Social Adjustment Scale (WSAS) - (Change between baseline and 12 month follow-up) |
This is a simple, reliable and valid measure of impaired functioning. It is a 5-item self-report measure that provides an experiential impact of a disorder from the patient's point of view. It looks at how the disorder impairs the patient's ability to function day to day on five dimensions: work, social life, home life, private life and close relationships. This scale ranges from 0-40 with 40 indicating a severe level of functional impairment. |
Administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Patient Health Questionnaire 9 (PHQ-9) - (Change between baseline and post-treatment) |
Items on the PHQ-9 reflect symptoms of Major Depressive Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-27 with higher scores indicating more severe depression. |
Administered at baseline (initial screening) and post-treatment (week 12 of treatment) |
|
| Secondary |
Patient Health Questionnaire 9 (PHQ-9) - (Change between baseline and 3 month follow-up) |
Items on the PHQ-9 reflect symptoms of Major Depressive Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-27 with higher scores indicating more severe depression. |
Administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Patient Health Questionnaire 9 (PHQ-9) - (Change between baseline and 12 month follow-up) |
Items on the PHQ-9 reflect symptoms of Major Depressive Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-27 with higher scores indicating more severe depression. |
Administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Generalized Anxiety Disorder 7 (GAD-7) - (Change between baseline and post-treatment) |
Items on the GAD-7 reflect symptoms of Generalized Anxiety Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-21 with higher scores indicating more severe anxiety. |
Administered at baseline (initial screening) and post-treatment (week 12 of treatment) |
|
| Secondary |
Generalized Anxiety Disorder 7 (GAD-7) - (Change between baseline and 3 month follow-up) |
Items on the GAD-7 reflect symptoms of Generalized Anxiety Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-21 with higher scores indicating more severe anxiety. |
Administered at baseline (initial screening) and 3 month follow-up (3 months after "post-treatment" which is week 12 of treatment) |
|
| Secondary |
Generalized Anxiety Disorder 7 (GAD-7) - (Change between baseline and 12 month follow-up) |
Items on the GAD-7 reflect symptoms of Generalized Anxiety Disorder, and provides a dimensional measure of symptom severity, self-administered by participants. Scores on this scale range from 0-21 with higher scores indicating more severe anxiety. |
Administered at baseline (initial screening) and 12 month follow-up (12 months after "post-treatment" which is week 12 of treatment) |
|
